Benjamin Thomas, MD
Ophthalmology · Jacksonville, FLNPI 1427290360
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,552 of the $62,238 with a category attached, or 76.4%. 19 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 46.7% of the total. Reporting peaked in 2024 at $24,716 and has fallen 83.5% since, to $4,074 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 210 payments — averaging $296.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$29K
- AbbVie$27K
- US Retina LLC$3K
- Alcon$1K
- Genentech USA, Inc.$741
- Novartis$410
- plus $1K from 13 others
Across 1,160 payments — averaging $2336.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1.5M
- Roche TCRC, Inc.$767K
- Bayer$312K
- Novartis$111K
- Boehringer Ingelheim International GmbH$70K
What the payments were for
- Consulting fees$1,6003%
- Speaking & faculty fees$47,55276%
- Travel & lodging$4,6878%
- Food & beverage$5,5949%
- Education$130%
- Ownership interest$1,1302%
- Other$1,6633%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 54 | $29,093 |
| AbbVie(2 entities) | 36 | $26,706 |
| US Retina LLC | 6 | $2,792 |
| Alcon | 10 | $1,015 |
| Genentech USA, Inc. | 31 | $741 |
| Novartis | 19 | $410 |
| Apellis Pharmaceuticals, Inc. | 11 | $280 |
| Bausch & Lomb Americas Inc. | 7 | $225 |
| Coherus Oncology, Inc. | 8 | $220 |
| Astellas Pharma US Inc | 4 | $192 |
| Alimera Sciences, Inc. | 7 | $156 |
| Biogen | 5 | $136 |
| Mallinckrodt Hospital Products Inc. | 3 | $75 |
| Notal Vision, Inc. | 1 | $46 |
| Oculus Surgical Inc. | 2 | $44 |
| Harrow Eye, LLC | 2 | $36 |
| Eyepoint US, Inc. | 2 | $26 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Sandoz | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,238 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EyleaAflibercept | 57 | $146,453 |
| VabysmoFaricimab-Svoa | 20 | $53,086 |
| Prednisolone Acetate | 286 | $13,737 |
| Ketorolac Tromethamine | 131 | $3,619 |
| Atropine Sulfate | 67 | $2,559 |
| Travoprost | 21 | $2,304 |
| Eplerenone | 18 | $1,737 |
| Brimonidine Tartrate | 81 | $1,703 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 99 | $1,319 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 12 | $906 |
| Gentamicin Sulfate | 81 | $872 |
| Latanoprost | 85 | $853 |
| Dorzolamide Hcl | 52 | $696 |
| Cyclopentolate Hcl | 37 | $540 |
| Timolol Maleate | 39 | $276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Regeneron Healthcare Solutions, Inc.Eylea | $29,093 | $146,45357 claims |
| Genentech USA, Inc.Vabysmo | $741 | $53,08620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Jacksonville
- Syril DorairajJacksonville$432K
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.